Kezar Life Sciences, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
49372L100
SEDOL
BFMLG29
CIK
0001645666
www.kezarlifesciences.com
LEI:
FIGI: BBG009DVZVV6
KZR
Kezar Life Sciences, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
Kezar Life Sciences, Inc.
ISIN
US49372L1008
TICKER
KZR
MIC
XNAS
REUTERS
KZR.OQ
BLOOMBERG
KZR US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 12.11.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The team at Kezar has made great progress towards completi...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.11.2024       Kezar Life Sciences
US49372L1008

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Kezar Life Sciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your righ...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the “Reverse Stock Split”). The Reverse Stock ...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the “Board”) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced key clinical development updates. The IDMC overseeing the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with AIH recommended that the trial may...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has received an unsolicited, non-binding proposal from Concentra Biosciences, LLC (“Concentra”), a Delaware limited liability company,...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Fri, 04.10.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the treatme...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 30.09.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary cessation in enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE clinical trial, pending further evaluation. PALIZADE is a g...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.09.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on ...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 13.08.2024       Kezar Life Sciences
US49372L1008

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “We are thrilled to announce completion of enrollmen...
Read More
Kezar Life Sciences
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S